ACA Implementation Policy Summit: Impact on the Patient with Diabetes


The summit will explore:

  • The current state of diabetes care in the United States, including its epidemiology, prevalence, and challenges relevant to care management.
  • The cost of diabetes care and the impact on various stakeholder groups, including individual patients, third-party payers, and health care systems.
  • Intended benefits of the ACA and how this shift in health care policy may impact diabetes care and outcomes.


To receive a maximum of 5.75 AMA PRA Category 1 Credits™ participants must complete an activity evaluation. To claim your CME credit, click "Take Course" on the right.

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows and any healthcare professional who treat patients with diabetes.

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Interpersonal and Communication Skills
Systems-based Practice
Topic Area: 
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Quality Improvement and Healthcare Delivery
General Endocrinology
Health Disparities
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 5.75 AMA PRA Category 1 Credits
  • 5.75 CME Certificate of Participation
Course opens: 
Course expires: 
Ronald Reagan Building and International Trade Center
1300 Pennsylvania Avenue, NW
Washington, DC
United States

Robert Vigersky, MD
Past President, Endocrine Society
Director, Diabetes Institute, Walter Reed National Military Medical Center

Ann Albright, PhD, RD
Director, Division of Diabetes Translation, Centers for Disease Control and Prevention

Sherita Golden, MD, MHS, FAHA
Director, Inpatient Diabetes Management Service, Division of Endocrinology, Diabetes, and Metabolism, Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University School of Medicine

Judith Fradkin, MD
Director, Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases

Harold D. Miller
President and CEO, Center for Healthcare Quality and Payment Reform

Jenifer Levinson
Member, JDRF Advocacy Committee

Courtney Lias, PhD
Director, Division of Chemistry and Toxicology Devices, Office of In Vitro Diagnostics and Radiological Devices, U.S. Food and Drug Administration

Jason Wexler, MD
Chair, Clinical Affairs Core Committee, Endocrine Society
Attending Physician, Section of Endocrinology, MedStar Washington Hospital Center

Zeke Emanuel, MD, PhD, MSc
Senior Fellow, Center for American Progress

Cynthia Magallon Puljic
Vice President, Health Innovations, YMCA of Memphis and the Mid-South 

R. James Dudl, MD
Diabetes Lead, Care Management Institute, Kaiser Permanente

Edward Damiano, PhD
Associate Professor, Biomedical Engineering, Boston University
Developer of Bionic Pancreas

Manny Hernandez
President, Diabetes Hands Foundation

Carter R. Blakey
Deputy Director, Office of Disease Prevention and Health Promotion, US Department of Health and Human Services

Kelly Close, MBA
President, Close Concerns, Inc.

Alvin C. Powers, MD
Director, Vanderbilt Diabetes Center


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships: 

Kelly Louise Close, MBA: Stock options in Abbott, Amylin, Alkermes, Asante, Avalere, Baxter, Bayer, Becton Dickinson, Biocon, Biodel, BodyMedia, Boehringer Ingelheim, Calbra, CanAm, Catabasis, Cebix, Cellnovo, CeQur, Dexcom. Enject, Eli Lilly, GI Dynamics,. Gilead, GSK, Insulet, InteKrin, Intuity Medical, JDFR., Johnson & Johnson, McKinsey & Company, Medtronic, Merck, Mesoblast, Metabolex, Novartis, Novo Nordisk, Orexigen, Pfizer, PhaseBio, Proteus Biomedical, Reata, Roche, Rhythm, Sanofi, Sensors for Medicine and Science, Servier, Tandem Diabetes, Telcare, Thermalin, Unomedical, Valeritas, Vivus, and Xeris.

Ed Damiano, PhD: Speaker, DexCom, Eli Lilly, Tandem Diabetes Care

Alvin C Powers, MD: Advisory Board Member, Boehringer Ingelheim Pharma GmbH & Co. KG, GNF/Novartis, Helmsley Trus; Research Grants, NIH, VA, JDRF

The following faculty reported no relevant financial relationships:  Ann Albright, PhD, RD; Carter Blakey; Robert James Dudl, MD; Ezekiel Emanuel, MD, PhD, MSc; Judith Fradkin, MD; Sherita Golden, MD; Manny Hernandez; Susan Hildebrandt; Jenifer Levinson; Courtney Lias; Harold D. Miller; Cynthia Magallon Puljic; Robert Vigersky, MD; Jason Wexler, MD 

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 5.75 AMA PRA Category 1 Credits
  • 5.75 CME Certificate of Participation